Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Landscape Professional Research Report 2025

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Landscape Professional Research Report 2025

Research Summary

Irritable Bowel Syndrome with Diarrhea (IBS-D) drugs refer to medications specifically designed to manage the symptoms associated with IBS-D, a subtype of Irritable Bowel Syndrome characterized by recurrent episodes of diarrhea along with abdominal pain and discomfort. These drugs aim to address the underlying factors contributing to diarrhea, such as increased gut motility and sensitivity. Commonly prescribed medications for IBS-D include antispasmodics, which help relax the muscles of the digestive tract, and certain medications that target serotonin receptors, modulating gut function. Additionally, bile acid sequestrants may be prescribed to reduce excess bile acids in the colon, which can contribute to diarrhea. Probiotics, dietary changes, and lifestyle modifications may also be recommended as part of the overall management strategy. Treatment plans are often individualized based on the specific symptoms and needs of each patient. While IBS-D drugs can help alleviate symptoms, it＇s important for individuals to work closely with healthcare providers to determine the most effective and personalized approach to managing their condition.

According to DIResearch's in-depth investigation and research, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Include:

Bausch Health

Allergan

Sebela Pharmaceuticals

Astellas Pharmaceuticals

Amneal Pharms

Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Segment Include:

XIFAXAN

Viberzi

Lotronex

Others

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Application Include:

Hospitals Pharmacy

Retail Pharmacy

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry PESTEL Analysis

Chapter 3: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Porter’s Five Forces Analysis

Chapter 4: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources